Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
Yet H Khor, Yvonne Ng, Hayley Barnes, Nicole SL Goh, Christine F McDonald, Anne E Holland
EUROPEAN RESPIRATORY REVIEW | EUROPEAN RESPIRATORY SOC JOURNALS LTD | Published : 2020
In addition to facilitating healthcare delivery planning, reliable information about prognosis is essential for treatment decisions in patients with idiopathic pulmonary fibrosis (IPF). This review aimed to evaluate the prognosis of patients with IPF without anti-fibrotic therapy. We included all cohort studies and the placebo arms of randomised controlled trials (RCTs) in IPF and follow-up of ≥12 months. Two reviewers independently evaluated studies for inclusion, assessed risk of bias and extracted data. A total of 154 cohort studies and 16 RCTs were included. The pooled proportions of mortality were 0.12 (95% CI 0.09-0.14) at 1-2 years, 0.38 (95% CI 0.34-0.42) between 2-5 years, and 0.69 ..View full abstract
Awarded by National Health and Medical Research Council
Y.H. Khor has received research fellowship support from the National Health and Medical Research Council (APP1093506). Funding information for this article has been deposited with the Crossref Funder Registry.